EA201792380A1 - Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен - Google Patents

Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен

Info

Publication number
EA201792380A1
EA201792380A1 EA201792380A EA201792380A EA201792380A1 EA 201792380 A1 EA201792380 A1 EA 201792380A1 EA 201792380 A EA201792380 A EA 201792380A EA 201792380 A EA201792380 A EA 201792380A EA 201792380 A1 EA201792380 A1 EA 201792380A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ligand
new
binding domain
epha4 inhibitors
inhibitors aimed
Prior art date
Application number
EA201792380A
Other languages
English (en)
Inventor
Маурицио Пеллечиа
Байнань Ву
Суриа Де
Original Assignee
Сэнфорд-Бёрнхэм Медикал Рисёрч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сэнфорд-Бёрнхэм Медикал Рисёрч Инститьют filed Critical Сэнфорд-Бёрнхэм Медикал Рисёрч Инститьют
Publication of EA201792380A1 publication Critical patent/EA201792380A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Заявленное изобретение относится к соединениям и фармацевтическим композициям, содержащим ингибиторы EphA4. Ингибиторы EphA4 и композиции с ними пригодны для лечения ALS.
EA201792380A 2015-04-29 2016-04-29 Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен EA201792380A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154670P 2015-04-29 2015-04-29
PCT/US2016/030070 WO2016176562A1 (en) 2015-04-29 2016-04-29 Novel epha4 inhibitors targeting its ligand binding domain

Publications (1)

Publication Number Publication Date
EA201792380A1 true EA201792380A1 (ru) 2018-04-30

Family

ID=57198786

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792380A EA201792380A1 (ru) 2015-04-29 2016-04-29 Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен

Country Status (10)

Country Link
US (1) US20180127464A1 (ru)
EP (1) EP3288932A4 (ru)
JP (1) JP2018519247A (ru)
KR (1) KR20170141730A (ru)
CN (1) CN107820495A (ru)
AU (1) AU2016255504A1 (ru)
BR (1) BR112017023261A2 (ru)
CA (1) CA2983277A1 (ru)
EA (1) EA201792380A1 (ru)
WO (1) WO2016176562A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110922349B (zh) * 2019-11-29 2022-04-26 四川大学 一种抗肿瘤化合物的合成及其在多发性骨髓瘤中的应用
EP4139326A4 (en) * 2020-04-23 2024-05-29 The Regents Of The University Of California COMPOUNDS TARGETING EPHA4 AND METHODS OF USE THEREOF
US11732007B2 (en) 2020-09-28 2023-08-22 The Regents Of The University Of California Therapeutic compounds and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
JP2007522096A (ja) * 2003-06-06 2007-08-09 メディミューン，インコーポレーテッド 癌の診断、治療、及び予防のためのＥｐｈＡ４及びＥｐｈＡ４変調因子の使用
KR20080105111A (ko) * 2006-02-28 2008-12-03 온코세라피 사이언스 가부시키가이샤 항 ＥｐｈＡ４ 항체의 효과기 기능을 이용한 세포 손상 방법
US20100197688A1 (en) * 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2011021581A1 (ja) * 2009-08-20 2011-02-24 学校法人早稲田大学 標的生体高分子の選択的標識剤
WO2011146595A2 (en) * 2010-05-21 2011-11-24 Siemens Healthcare Diagnostics Inc. Zwitterionic reagents
EP2582715B1 (en) * 2010-06-16 2018-11-28 The Administrators of the Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
FR3000494B1 (fr) * 2012-12-28 2015-08-21 Oribase Pharma Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases

Also Published As

Publication number Publication date
BR112017023261A2 (pt) 2018-08-07
AU2016255504A1 (en) 2017-11-16
EP3288932A1 (en) 2018-03-07
WO2016176562A1 (en) 2016-11-03
EP3288932A4 (en) 2018-12-05
CN107820495A (zh) 2018-03-20
US20180127464A1 (en) 2018-05-10
CA2983277A1 (en) 2016-11-03
JP2018519247A (ja) 2018-07-19
KR20170141730A (ko) 2017-12-26

Similar Documents

Publication Publication Date Title
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
EA201591599A1 (ru) Ингибиторы ido
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201690306A1 (ru) Ингибиторы ido
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201690152A1 (ru) Ингибиторы ido
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201592143A1 (ru) Новые бициклические ингибиторы бромодомена
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201890052A1 (ru) Регуляторы nrf2
EA201690027A1 (ru) Ингибиторы ido
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
EA201591961A1 (ru) Ингибиторы акк и их применение